No Data
HBM Obtains US FDA Clearance for New Drug
01:42 AM EDT, 06/28/2022 (MT Newswires) -- HBM Holdings (HKG:2142) obtained clearance of Investigational New Drug from the US Food and Drug Administration for B7H4X4-1BB bispecific antibody HBM7008.
HBM Doses First Patient in Phase I Clinical Trial of Cancer Drug
06:48 AM EDT, 05/26/2022 (MT Newswires) -- HBM Holdings (HKG:2142) dosed the first patient in its Phase I clinical trial of HBM7008, according to a Thursday disclosure. The study will evaluate the sa
And Platinum Pharmaceuticals-BRV 2021 Annual report
HBM Appoints New Chief Medical Officer
Changes in Hong Kong stocks | Platinum Pharmaceuticals-B (02142) rose more than 4% to receive an increase in Credit Suisse's target price of 8.6% to HK $7.6
Zitong Financial APP learned that Credit Suisse released a research report that maintained the "outperform" rating of Platinum Pharmaceuticals-B (02142) because it believed that the group was a differentiated biotech company with its own antibody platform to provide power for internal drug pipelines. raise the 2022-24 earnings per share forecast of 14.1%, 2.6% and 1.5%, with the target price raised from HK $7 to HK $7.6. As of 09:38, it was up 4.43% to quote HK $4.24, with a turnover of 5.4924 million. According to the report, Heplatinum announced a pre-clinical relationship with AstraZeneca PLC (AstraZeneca).
HBM Strikes Cancer Drug Licensing Deal with AstraZeneca; Shares Rally 26%
10:38 PM EDT, 04/06/2022 (MT Newswires) -- HBM Holdings (HKG:2142) struck a deal to license its HBM7022 antibody to AstraZeneca, according to a Thursday filing. Under the agreement, AstraZeneca will
And Platinum Pharmaceuticals-B: date of Board meeting
HBM Gets Nod to Start Australia Clinical Trial of Solid Tumor Drug
09:34 PM EST, 02/27/2022 (MT Newswires) -- HBM Holdings (HKG:2142) obtained regulatory approval to begin the phase I clinical trial in Australia of HBM7008, according to a Monday disclosure. The stud
HBM Doses First Patient in Clinical Trial for Melanoma Treatment
08:26 PM EST, 01/23/2022 (MT Newswires) -- HBM Holdings (HKG:2142) dosed the first patient with HBM4003 antibody in a phase Ib/IIa clinical trial in China for treating advanced melanoma and other sol
Investment rating and target price of Chinese medicine, R & D, medical equipment, distribution and traditional Chinese medicine stocks in the "Bank of China report" (table)
Morgan Stanley publishes research report For Chinese-funded medicine, research and development, medical equipment, The investment rating and target price of distribution and traditional Chinese medicine stocks are listed as follows: shares | Investment rating | Target price (HK $) Hengduan Pharmaceutical (600276.SH) | increase holdings | 72 yuan INNOVENT BIO (01801.HK) | increase holdings | 95 yuan Wuxi Biologics (02269.HK) | increase holdings | 175 yuan innovative drugs / biomedical stocks and reputation-B (02256.HK) | increase holdings | 13.6 yuan Kang Fang Bio-B (09926. HK) | increased holdings | CNY 68.6% Corning Jerry Pharmaceuticals-B (099)
Loading...